<SEC-DOCUMENT>0001615774-17-004132.txt : 20170808
<SEC-HEADER>0001615774-17-004132.hdr.sgml : 20170808
<ACCEPTANCE-DATETIME>20170808061841
ACCESSION NUMBER:		0001615774-17-004132
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20170808
FILED AS OF DATE:		20170808
DATE AS OF CHANGE:		20170808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		171013158

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>s107080_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the Month of August 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commission
File Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 11pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; font-size: 12pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD NOWRAP STYLE="width: 14%; border-bottom: Black 0.5pt solid; font-size: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
    LIMITED</B></FONT></TD>
    <TD STYLE="width: 43%; font-size: 12pt"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    of Registrant)</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 11pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 0.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level
    3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia 3053</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive
    office)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F &#9746; &nbsp;Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9744; &nbsp; No &#9746;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IMMURON
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXPLANATORY
NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Immuron
Limited (the &ldquo;Company&rdquo;) published a two public announcements (the &ldquo;Public Releases&rdquo;) to the Australian
Securities Exchange on August 8, 2017 announcing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                         Change of Director&rsquo;s Interest Notice for Immuron Director, Mr Peter Anastasiou
                                         who purchase ASX shares on-market; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">that
                                         Immuron is to Present C.difficile results data at the 2017 ClostPath Conference in Michigan,
                                         USA.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
copy of each Public Release is attached as an exhibit to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
report on Form 6-K (including the exhibits hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt Calibri, Helvetica, Sans-Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 6%; font: 10pt Calibri, Helvetica, Sans-Serif; border-bottom: Black 1pt solid"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 83%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="s107080_ex99-1.htm">99.1</A></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="s107080_ex99-2.htm">99.2</A></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="s107080_ex99-1.htm">Appendix 3Y - Change of Director&rsquo;s Interest Notice (PA)</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="s107080_ex99-2.htm">Public Release - Immuron to Present C.difficile Data at ClostPath 2017 Conference</A></FONT></P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
    LIMITED</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img004_v1.jpg" ALT="(SIGNATURE)"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;August
    8, 2017 &nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Peter Vaughan</FONT></TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Peter Vaughan<BR> Joint Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s107080_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; border-bottom: Black 2.5pt solid; text-align: right; text-indent: -42.55pt">Appendix
3Y<BR>
Change of Director&rsquo;s Interest Notice</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: right; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: right; text-indent: -42.55pt"><I>Rule
3.19A.2</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: center; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: center; text-indent: -42.55pt"><FONT STYLE="font-size: 10pt">Appendix
3Y</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Change of Director&rsquo;s Interest
Notice</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 4.9pt 0pt 0; text-align: justify">Information or documents
not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX&rsquo;s property
and may be made public.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 4.9pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><B>Introduced
30/9/2001. Amended 01/01/11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 21%; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 5.4pt; background-color: #E6E6E6; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;Name of Entity: </B></FONT></TD>
    <TD STYLE="width: 79%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;</B>Immuron Limited&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ASX:IMC)</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 5.4pt; background-color: #E6E6E6; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;ABN:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;80 063 114 045</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We (the entity) give
ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the
Corporations Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 23%; border: Black 1pt solid; padding: 2pt 5.4pt; background-color: #E6E6E6; font-weight: bold; text-align: justify; font-family: Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Director:</FONT></TD>
    <TD STYLE="width: 77%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mr Peter Anastasiou</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; background-color: #E6E6E6; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Date of Last Notice:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">20 June 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><B>Part
1 - Change of director&rsquo;s relevant interests in securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><I>In the case of a trust,
this includes interests in the trust made available by the responsible entity of the trust</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Note: In the case of a company,
interests which come within paragraph (i) of the definition of &ldquo;notifiable interest of a director&rdquo; should be disclosed
in this part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt"><B>Direct or Indirect Interest</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Indirect</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Nature of indirect
        interest</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>(including registered
        holder)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Note:
        Provide details of the circumstances giving rise to the relevant interest.</FONT></P></TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">Director
        Related Entity</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt"><B>Date of change</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </FONT>3 August 2017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </FONT>4 August 2017</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>No. of securities held prior to change</B></FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Options</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Direct</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Indirect</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">14,971,644</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">4,726,409</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; background-color: #E6E6E6; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>14,971,644</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>4,726,409</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; text-align: left; padding-left: 5.4pt; padding-bottom: 9pt"><FONT STYLE="font-size: 10pt"><B>Class</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; padding-bottom: 9pt"><FONT STYLE="font-size: 10pt">Fully paid ordinary shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Number acquired</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Options</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Direct</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Indirect</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">a)&nbsp;239,166</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">b)&nbsp;&nbsp;&nbsp;60,834</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; background-color: #E6E6E6; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>300,000</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt">&mdash;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Number disposed</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Options</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Direct</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Indirect</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; background-color: #E6E6E6; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 56%; border-top: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">+ See chapter 19 for defined terms.</FONT></TD>
    <TD STYLE="width: 44%; border-top: Black 0.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">01/01/2011</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0.25in"><FONT STYLE="font-size: 10pt">Appendix 3Y Page 1</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in; border-bottom: Black 1.5pt solid">Appendix
3Y<BR>
Change of Director&rsquo;s Interest Notice</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Value/Consideration</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Note:
        If consideration is non-cash, provide details and estimated valuation</FONT></P></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.55pt; text-align: justify; text-indent: -0.25in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </FONT>AUD $47,711.46</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.55pt; text-align: justify; text-indent: -0.25in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </FONT>AUD $12,166.80</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>No. of securities held after change</B></FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><B>Shares</B></TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: center; padding-left: 5.4pt"><B>Options</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">Direct</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt">&mdash;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">Indirect</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">15,271,644</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">4,726,409</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; background-color: #E6E6E6; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><B>Total</B></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>15,271,644</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; padding-right: 5.4pt; text-align: right; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>4,726,409</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Nature of change</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Example:
        On-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in
        buy-back</FONT></P></TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt">On market acquisition.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><B>Part
2 &ndash; Change of director&rsquo;s interests in contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: left; text-indent: 0in">Note: In the
case of a company, interests which come within paragraph (ii) of the definition of &ldquo;notifiable interest  of a director&rdquo;
should be disclosed in this part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-bottom: 6pt; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Detail of contract</B></FONT></TD>
    <TD STYLE="width: 62%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-bottom: 6pt; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Nature of interest</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; background-color: #D9D9D9; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Name of registered
        holder</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>(if issued securities)</B></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-bottom: 6pt; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Date of change</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; background-color: #D9D9D9; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>No. and class of securities
        to which interest related prior to change</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Note:
        Details are only required for a contract in relation to which the interest has changed</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-bottom: 6pt; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Interest acquired</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-bottom: 6pt; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Interest disposed</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; background-color: #D9D9D9; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Value/Consideration</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note: If consideration is non-cash, provide
        details and an estimated valuation</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-bottom: 6pt; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Interest after change</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><B>Part
3 &ndash; +Closed period</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</B></FONT></TD>
    <TD STYLE="width: 62%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>If so, was prior written clearance provided to allow the trade to proceed during this period?</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #D9D9D9; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>If prior written clearance was provided, on what date was this provided?</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Tahoma, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img005_v1.jpg" ALT="(CFO LOGO)">&nbsp;</FONT></TD>
    <TD STYLE="width: 92%; border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The CFO Solution</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7
August 2017</FONT></P>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 56%; border-top: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">+ See chapter 19 for defined terms.</FONT></TD>
    <TD STYLE="width: 44%; border-top: Black 0.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">01/01/2011</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-right: 0.25in"><FONT STYLE="font-size: 10pt">Appendix 3Y Page 2</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"></P>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt">&nbsp;</P>

<P STYLE="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: left; text-indent: -42.55pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>s107080_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="img001_v1.jpg" ALT="(IMMURON LIMITED LOGO)">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
to Present C.difficile Data at ClostPath 2017 Conference</B></FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Melbourne,
Australia, 8 August 2017:</B> Australian microbiome biopharmaceutical company Immuron Limited (ASX: IMC) today announced that
its pre-clinical data on IMM-529 targeting Clostridium difficile infections (CDI) will be presented at the 10<SUP>th</SUP> International
Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClostPath 10) in Ann Arbor, Michigan (USA) from 7<SUP>th
</SUP>&ndash; 10<SUP>th</SUP> August 2017.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clostpath
10 is a global leading conference of clostridial research scientists and clinicians for forefront research on the molecular biology
of clostridia and their role in health and disease. The opportunity for Immuron to present its findings to this conference is
highly significant and as such also validates the Company&rsquo;s success and progress to date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associate
Professor Dr Dena Lyras from Monash University (Melbourne, Australia) said;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;The
results of our IMM-529 pre-clinical studies highlight the potential of this compound in patients afflicted with CDI, especially
given the current lack of alternative treatments to broad spectrum antibiotics.</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
are proud of the work that has been completed by the teams at Monash, in collaboration with Immuron, and we look forward to presenting
the data at ClostPath 10, the leading conference on Clostridia.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">The
preliminary program for the ClostPath 10 conference is available</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">from
the ClostPath 10 website.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron&rsquo;s
Interim-Chief Executive Officer, Dr Jerry Kanellos, added;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Our
Principle Investigator, Professor Dena Lyras is a world renowned expert on Clostridium difficle and was the first researcher to
report on the clinical importance of toxin B in the pathology of the disease. </I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>One
of Immuron&rsquo;s key corporate objectives moving forward is to significantly enhance the visibility of our science to the relevant
medical, scientific, and patient advocate communities across the world. We are pleased to support the presentation of the preclinical
program at such an important meeting and also plan to showcase the results, advances, and opportunities of Immuron&rsquo;s programs
at many upcoming conferences.&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img002_v1.jpg" ALT="(IMMURON LOGO)"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="img003_v1.jpg" ALT="(IMMURON LIMITED LOGO)">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: rgb(31,73,125) 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IMM-529
                                         is an exciting asset given its unique and targeted mechanism of action. It was developed
                                         specifically to neutralize C. difficile, while leaving the microbiome intact, which is
                                         a key component of controlling the virulence of this dreaded disease.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 25.5pt 0pt 28.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron&rsquo;s
IMM-529 program is unique as it not only targets toxin B, but also the spores and the vegetative cells, which are thought to be
the primary cause of the recurrences of C. <I>difficile</I> which make it so difficult to treat. IMM-529 is a natural biological
product which is intended to prevent and treat C. <I>difficile</I> infections whilst not destroying the microbiome like antibiotic
treatments, allowing the microbiome to return to a healthy state.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
antibodies in IMM-529 have demonstrated to be cross reactive with a variety of human and animal C. <I>difficile</I> isolates and
to their associated Toxin B, vegetative cell and spore components. The antibodies in IMM-529 have also been shown to neutralise
Toxin B from a historical C. <I>difficile</I> strain (630), and from a hypervirulent (HV) strain which caused the recent worldwide
outbreaks.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11.35pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pathogenic
C. <I>difficile</I> strains colonize in the human gut and produce toxins that mediate gut damage and cause diarrhea. IMM-529 targets
the specific site of infection. The antibodies survive transit through the stomach and remain functional in the large intestine.
The antibodies in IMM529 result in localised toxin B neutralization at the site of infection before significant damage is done,
bind to spores and vegetative cells in the gut, and prevent toxin B translocation into the blood supply.&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">---
END ---</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #006FC0"><B>COMPANY
    CONTACT:</B></FONT></TD>
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #006FC0"><B>US INVESTORS
    RELATIONS:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry Kanellos</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Cunningham</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim-Chief Executive Officer</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip Companies, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUS Ph: +61 (0)3 9824 5254</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Ph: +1 (407) 644 4256, (ext. 107)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jerrykanellos@immuron.com</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jon@redchip.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #006FC0"><B>AUSTRALIA INVESTORS RELATIONS:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #006FC0"><B>US PUBLIC RELATIONS:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Taylor</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Fischgrund</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NWR Communications</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FischTank - Marketing and PR</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUS ph: Ph: +61 (0)4 1203 6231</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Ph: +1 (646) 699 1148</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">peter@nwrcommunications.com.au</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eric@fischtankpr.com</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="img002_v1.jpg" ALT="(IMMURON LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="img003_v1.jpg" ALT="(IMMURON LIMITED LOGO)">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: rgb(31,73,125) 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ABOUT
IMMURON:</U></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (NASDAQ: IMRN; ASX: IMC), is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics
for the treatment of gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development
therapeutic cycle. The Company currently markets and sells Travelan&reg; for the prevention of Travellers&rsquo; Diarrhea and
its lead clinical candidate, IMM-124E, is in Phase 2 clinical trials for NASH, ASH and Pediatric NAFLD. Immuron&rsquo;s second
clinical stage asset, IMM-529, is targeting C. <I>difficile</I> Infections (CDI). These products together with the Company&rsquo;s
other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large
unmet need in the global immunotherapy market.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: http://www.immuron.com</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product development programs and any other statements that are not historical
facts. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the
early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img002_v1.jpg" ALT="(IMMURON LOGO)"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img004_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img004_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ *P!Q P$1  (1 0,1 ?_$ 'P   (#  ,!
M       & P0% 0('" $!                     !   0,# @0#! 4*!P$
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.. T!H#0&@- : T!H/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img005_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img005_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ '@ R P$1  (1 0,1 ?_$ 'H   (# 0$
M      <)! 4*!@@! 0$                    !$   !@(!  8'!P4
M   " P0%!@<!" D $1(3% HR-&05-54W(F,6-E<8.B%F%SG:$0$  @(# 0
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, "IZI[5Z7W'0C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 3@$L P$1  (1 0,1 ?_$ +0   ,! 0$! 0$
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M&L2.Y=[OE/55"ZO&JI%&%F9H']1:'W%C4I([1!BM0W1I836/Q)5?;$WC!X?
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MLN&*QQ+I$4M!  0 $ !  0 $ !  0 $ !  0 $ !  0 $ !  0 $ !  0 $
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M(?7)"E?=)/R0[7\[E3_BFA.AY%&I_)IEKSG(V\?Q.X78*!<::(I1/PG7.];
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:2_CA^A]IQME)8MM_'$LO>:.K1+X)1(*Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X0=117AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    ;    <@$R  (    4    C8=I  0    !    I    -    !(
M 0   $@    !061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W, ,C Q-SHP.#HP
M." Q,SHP,SHQ.        Z !  ,    !__\  * "  0    !   "MZ #  0
M   !    :0         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   8;
M     $@    !    2     '_V/_@ !!*1DE&  $" 0!( $@  /_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ & "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MW'[K_]G_[0OZ4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M        .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))300*       !   X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -'    !@              :0   K<    ) &D ;0!G #  ,  R
M %\ =@ Q     0                         !              *W
M:0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M:0    !29VAT;&]N9P   K<    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   &D     4F=H=&QO;F<
M  *W     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     3_P        .$))3001       ! 0 X0DE-!!0       0
M   !.$))300,      8W     0   *     8   !X   +0    8; !@  ?_8
M_^  $$I&248  0(! $@ 2   _^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  8 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M@G$O %M9)-3_ -]O\A>:)('CH_+LF/L\0^?<?NO_V0 X0DE-!"$      %,
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     2 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3     0 X0DE-! 8
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2=W)S\^_^X
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MY_<Q^'^Y>H>6;"T3RGIED(U^K&QAC:*@XE6B'($?Y537-3FD?$)Z\3L<41P
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MNM8NI!X-.]/N!&9$=-BCRC#_ $KC3U>:7.<S_G22N34$<_O9RY_RF+?KKEP
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M?^)\LNCV1@'0G_.:9=MZD]1'_-2^X_-SSM,"&U=T!_WW'&GZDRR/9NG'\/\
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MC2KMOFT8_B<D.PY_SHL#[08_YLOL0TO_ #D;IX_NM%E;_7F4?J0Y(=A'K/\
MV+ ^T(Z0_P!E_P =0LO_ #D;/7]UHB@?Y4Y/ZDRT=A#K/_8_\>:S[0RZ0_V7
M_'4*_P#SD7K!^QI%N/\ 6D<_JIA'8</YQ8'V@R?S0A9O^<A?-+5X6-G'X?#(
MWZWRT=B8NIG_ +%K/;^;H(?[+_BD')^??GEJ\?JJ?*&OZV.3'8^#S^;4>W-1
M_1^2&E_/#\P'%!=Q1_ZL$?\ $')CLG3CI_LI,#VSJ3_$/]+% R_F[^8$AWU:
M1?\ 46-?U)E@[-P#^$?[)JEVIJ3_ !G_ &*%D_,OSU)7EK5WOX2%?^(TRP:'
M /X(-9U^H/\ '+YH*?SEYIG'[[5;N3_6GE/_ !MED=/C'*,/]+%KEJ<IYRE_
MII(.36M5D_O+J5_]:1S^LY8(1'0-1G(\R?FAFNYV^TW+Y[_KR3%;Z\GB/N&&
MV-.]>7^8X&37K2_SG[\5:,CGJQ^_%6N3>)Q5O%5N*NQ5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL537RO\ \=*;_F U+_J!GS'U/T#^
MOC_Z:0<C3?5_F9/^F<W_TR%]!UOFW^XZZZG_ '1)_P TYW@S0_G#_3/G1P9/
MYI_TJS] ZW_U;KK_ )$2?\TX?&A_.'^F7P,G\T_)WZ!UO_JW77_(B3_FG'QH
M?SA_IE\#)_-/R=^@=;_ZMUU_R(D_YIQ\>'\X?Z9? R?S3\G?H'6_^K==?\B)
M/^:<?&A_.'^F7P,G\T_)WZ!UO_JW77_(B3_FG'QH?SA_IE\#)_-/R=^@=;_Z
MMUU_R(D_YIQ\:'\X?Z9? R?S3\G?H'6_^K==?\B)/^:<?'A_.'^F7P,G\T_)
MWZ!UO_JW77_(B3_FG'QH?SA_IE\#)_-/R=^@=;_ZMUU_R(D_YIQ\:'\X?Z9?
M R?S3\G?H'6_^K==?\B)/^:<?&A_.'^F7P,G\T_)WZ!UO_JW77_(B3_FG'QH
M?SA_IE\#)_-/R;_06N?]6ZZ_Y$2?\TX^-#^</],O@9/YI^37Z!US_JVW7_(B
M7_FG'QH?SA_IE\#)_-/R=^@=<_ZMMU_R(E_YIQ\:'\X?Z9? R?S3\F_T#KG_
M %;;K_D1+_S3CXT/YP_TR/ R?S3\G?H/7/\ JVW7_(B7_FG'QH?SA_IE\#)_
M-/R=^@M<_P"K;=_\B)?^:<?&A_.'^F7\OD_FG_2N_06N?]6V[_Y$2_\ -./C
M0_G#_3+^7R?S3_I7?H+7/^K;=_\ (B7_ )IQ\:'\X?Z9?R^3^:?]*[]!:Y_U
M;;O_ )$2_P#-./C0_G#_ $R_E\G\T_Z5WZ"US_JVW?\ R(E_YIQ\:'\X?Z9?
MR^3^:?\ 2N_06N?]6V[_ .1$O_-./C0_G#_3+^7R?S3_ *5WZ"US_JVW?_(B
M7_FG'QH?SA_IE_+Y/YI_TKOT%KG_ %;;O_D1+_S3CXT/YP_TR_E\G\T_Z5WZ
M"US_ *MMW_R(E_YIQ\:'\X?Z9?R^3^:?]*[]!:Y_U;;O_D1+_P TX^-#^</]
M,OY?)_-/^E=^@M<_ZMMW_P B)?\ FG'QH?SA_IE_+Y/YI_TKOT%KG_5MN_\
MD1+_ ,TX^-#^</\ 3+^7R?S3_I7?H+7/^K;=_P#(B7_FG'QH?SA_IE_+Y/YI
M_P!*[]!:Y_U;;O\ Y$2_\TX^-#^</],OY?)_-/\ I7?H+7/^K;=_\B)?^:<?
M&A_.'^F7\OD_FG_2N_06N?\ 5MN_^1$O_-./C0_G#_3+^7R?S3_I7?H+7/\
MJVW?_(B7_FG'QH?SA_IE_+Y/YI_TKOT%KG_5MN_^1$O_ #3CXT/YP_TR_E\G
M\T_Z5WZ"US_JVW?_ "(E_P":<?&A_.'^F7\OD_FG_2N_06N?]6V[_P"1$O\
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MZMMW_P B)?\ FG'QH?SA_IE_+Y/YI_TKOT%KG_5MN_\ D1+_ ,TX^-#^</\
M3+^7R?S3_I7?H+7/^K;=_P#(B7_FG'QH?SA_IE_+Y/YI_P!*[]!:Y_U;;O\
MY$2_\TX^-#^</],OY?)_-/\ I7?H+7/^K;=_\B)?^:<?&A_.'^F7\OD_FG_2
MN_06N?\ 5MN_^1$O_-./C0_G#_3+^7R?S3_I7?H+7/\ JVW?_(B7_FG'QH?S
MA_IE_+Y/YI_TKOT%KG_5MN_^1$O_ #3CXT/YP_TR_E\G\T_Z5WZ"US_JVW?_
M "(E_P":<?&A_.'^F7\OD_FG_2N_06N?]6V[_P"1$O\ S3CXT/YP_P!,OY?)
M_-/^E=^@M<_ZMMW_ ,B)?^:<?&A_.'^F7\OD_FG_ $KOT%KG_5MN_P#D1+_S
M3CXT/YP_TR_E\G\T_P"E=^@M<_ZMMW_R(E_YIQ\:'\X?Z9?R^3^:?]*[]!:Y
M_P!6V[_Y$2_\TX^-#^</],OY?)_-/^E=^@M<_P"K;=_\B)?^:<?&A_.'^F7\
MOD_FG_2N_06N?]6V[_Y$2_\ -./C0_G#_3+^7R?S3_I7?H+7/^K;=_\ (B7_
M )IQ\:'\X?Z9?R^3^:?]*[]!:Y_U;;O_ )$2_P#-./C0_G#_ $R_E\G\T_Z5
MWZ"US_JVW?\ R(E_YIQ\:'\X?Z9?R^3^:?\ 2N_06N?]6V[_ .1$O_-./C0_
MG#_3+^7R?S3_ *5WZ"US_JVW?_(B7_FG'QH?SA_IE_+Y/YI_TKOT%KG_ %;;
MO_D1+_S3CXT/YP_TR_E\G\T_Z5WZ"US_ *MMW_R(E_YIQ\:'\X?Z9?R^3^:?
M]*[]!:Y_U;;O_D1+_P TX^-#^</],OY?)_-/^E=^@M<_ZMMW_P B)?\ FG'Q
MH?SA_IE_+Y/YI_TKOT%KG_5MN_\ D1+_ ,TX^-#^</\ 3+^7R?S3_I7?H+7/
M^K;=_P#(B7_FG'QH?SA_IE_+Y/YI_P!*[]!:Y_U;;O\ Y$2_\TX^-#^</],O
MY?)_-/\ I7?H+7/^K;=_\B)?^:<?&A_.'^F7\OD_FG_2N_06N?\ 5MN_^1$O
M_-./C0_G#_3+^7R?S3_I7?H+7/\ JVW?_(B7_FG'QH?SA_IE_+Y/YI_TKOT%
MKG_5MN_^1$O_ #3CXT/YP_TR_E\G\T_Z5WZ"US_JVW?_ "(E_P":<?&A_.'^
MF7\OD_FG_2N_06N?]6V[_P"1$O\ S3CXT/YP_P!,OY?)_-/^E=^@M<_ZMMW_
M ,B)?^:<?&A_.'^F7\OD_FG_ $J:^6]%UE-2E+Z?<J#8Z@H)AD'Q-8S*!N.I
MRG/FB0!8^N/_ $T<G389B1-'Z,G_ $SF_P#_U/5.*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
/*NQ5V*NQ5V*NQ5V*O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img003_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img003_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ / #F P$1  (1 0,1 ?_$ +$   (# 0$!
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MCU"QN-%1MY#(P.\TFKE[TV8W6X*I\/QM"V!L2'D.U3Y\I2P4I3YMOGAUNGL
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'IR?Y[U__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
